Cargando…

Galantamine tethered hydrogel as a novel therapeutic target for streptozotocin-induced Alzheimer's disease in Wistar rats

Amyloid-β (Aβ) plaque formation, neuronal cell death, and cognitive impairment are the unique symptoms of Alzheimer's disease (AD). No single step remedy is available to treat AD, so the present study aimed to improve the drugability and minimize the abnormal behavioral and biochemical activiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Rajkumar, Manickam, Sakthivel, Murugesan, Senthilkumar, Kottaisamy, Thangaraj, Ramasundaram, Kannan, Soundarapandian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058960/
https://www.ncbi.nlm.nih.gov/pubmed/35510084
http://dx.doi.org/10.1016/j.crphar.2022.100100
_version_ 1784698224318087168
author Rajkumar, Manickam
Sakthivel, Murugesan
Senthilkumar, Kottaisamy
Thangaraj, Ramasundaram
Kannan, Soundarapandian
author_facet Rajkumar, Manickam
Sakthivel, Murugesan
Senthilkumar, Kottaisamy
Thangaraj, Ramasundaram
Kannan, Soundarapandian
author_sort Rajkumar, Manickam
collection PubMed
description Amyloid-β (Aβ) plaque formation, neuronal cell death, and cognitive impairment are the unique symptoms of Alzheimer's disease (AD). No single step remedy is available to treat AD, so the present study aimed to improve the drugability and minimize the abnormal behavioral and biochemical activities in streptozotocin (STZ) induced AD experimental Wistar rats. In particular, we explored the utilization of methacrylated gelatin (GelMA), which is a biopolymeric hydrogel that mimics the natural tissue environment. The synthesized biopolymeric gel contained the drug galantamine (Gal). Investigations were conducted to evaluate the behavioral activities of STZ-induced AD experimental rats under STZ ​+ ​GelMA ​+ ​Gal treatment. The experimental groups comprised the control and STZ, STZ ​+ ​GelMA, STZ ​+ ​Gal, and STZ ​+ ​GelMA ​+ ​Gal (10 ​mg/kg) treated rats. Intracerebroventricular STZ ensures cognitive decline in terms of an increase in the escape latency period, with a decrease in the spontaneous alteration of behavioral activities. Our results indicated decrease Aβ aggregation in the hydrogel-based drug treatment group and significant decreases in the levels of acetylcholinesterase and lipid peroxidation (p ​< ​0.001). In addition, the glutathione and superoxide dismutase activities appeared to be improved in the STZ ​+ ​GelMA ​+ ​Gal group compared with the other treatment groups. Furthermore, histopathological and immunohistochemical experiments showed that the GelMA ​+ ​Gal treated AD rats exhibited significantly improved behavioral and biochemical activities compared with the STZ treated AD rats. Therefore, STZ ​+ ​GelMA ​+ ​Gal administration from the pre-plaque stage may have a potential clinical application in the prevention of AD. Thus, we conclude that hydrogel-based Gal drugs are efficient at decreasing Aβ aggregation and improving the neuroinflammatory process, antioxidant activity, and neuronal growth.
format Online
Article
Text
id pubmed-9058960
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-90589602022-05-03 Galantamine tethered hydrogel as a novel therapeutic target for streptozotocin-induced Alzheimer's disease in Wistar rats Rajkumar, Manickam Sakthivel, Murugesan Senthilkumar, Kottaisamy Thangaraj, Ramasundaram Kannan, Soundarapandian Curr Res Pharmacol Drug Discov Research Article Amyloid-β (Aβ) plaque formation, neuronal cell death, and cognitive impairment are the unique symptoms of Alzheimer's disease (AD). No single step remedy is available to treat AD, so the present study aimed to improve the drugability and minimize the abnormal behavioral and biochemical activities in streptozotocin (STZ) induced AD experimental Wistar rats. In particular, we explored the utilization of methacrylated gelatin (GelMA), which is a biopolymeric hydrogel that mimics the natural tissue environment. The synthesized biopolymeric gel contained the drug galantamine (Gal). Investigations were conducted to evaluate the behavioral activities of STZ-induced AD experimental rats under STZ ​+ ​GelMA ​+ ​Gal treatment. The experimental groups comprised the control and STZ, STZ ​+ ​GelMA, STZ ​+ ​Gal, and STZ ​+ ​GelMA ​+ ​Gal (10 ​mg/kg) treated rats. Intracerebroventricular STZ ensures cognitive decline in terms of an increase in the escape latency period, with a decrease in the spontaneous alteration of behavioral activities. Our results indicated decrease Aβ aggregation in the hydrogel-based drug treatment group and significant decreases in the levels of acetylcholinesterase and lipid peroxidation (p ​< ​0.001). In addition, the glutathione and superoxide dismutase activities appeared to be improved in the STZ ​+ ​GelMA ​+ ​Gal group compared with the other treatment groups. Furthermore, histopathological and immunohistochemical experiments showed that the GelMA ​+ ​Gal treated AD rats exhibited significantly improved behavioral and biochemical activities compared with the STZ treated AD rats. Therefore, STZ ​+ ​GelMA ​+ ​Gal administration from the pre-plaque stage may have a potential clinical application in the prevention of AD. Thus, we conclude that hydrogel-based Gal drugs are efficient at decreasing Aβ aggregation and improving the neuroinflammatory process, antioxidant activity, and neuronal growth. Elsevier 2022-04-17 /pmc/articles/PMC9058960/ /pubmed/35510084 http://dx.doi.org/10.1016/j.crphar.2022.100100 Text en © 2022 Published by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Rajkumar, Manickam
Sakthivel, Murugesan
Senthilkumar, Kottaisamy
Thangaraj, Ramasundaram
Kannan, Soundarapandian
Galantamine tethered hydrogel as a novel therapeutic target for streptozotocin-induced Alzheimer's disease in Wistar rats
title Galantamine tethered hydrogel as a novel therapeutic target for streptozotocin-induced Alzheimer's disease in Wistar rats
title_full Galantamine tethered hydrogel as a novel therapeutic target for streptozotocin-induced Alzheimer's disease in Wistar rats
title_fullStr Galantamine tethered hydrogel as a novel therapeutic target for streptozotocin-induced Alzheimer's disease in Wistar rats
title_full_unstemmed Galantamine tethered hydrogel as a novel therapeutic target for streptozotocin-induced Alzheimer's disease in Wistar rats
title_short Galantamine tethered hydrogel as a novel therapeutic target for streptozotocin-induced Alzheimer's disease in Wistar rats
title_sort galantamine tethered hydrogel as a novel therapeutic target for streptozotocin-induced alzheimer's disease in wistar rats
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058960/
https://www.ncbi.nlm.nih.gov/pubmed/35510084
http://dx.doi.org/10.1016/j.crphar.2022.100100
work_keys_str_mv AT rajkumarmanickam galantaminetetheredhydrogelasanoveltherapeutictargetforstreptozotocininducedalzheimersdiseaseinwistarrats
AT sakthivelmurugesan galantaminetetheredhydrogelasanoveltherapeutictargetforstreptozotocininducedalzheimersdiseaseinwistarrats
AT senthilkumarkottaisamy galantaminetetheredhydrogelasanoveltherapeutictargetforstreptozotocininducedalzheimersdiseaseinwistarrats
AT thangarajramasundaram galantaminetetheredhydrogelasanoveltherapeutictargetforstreptozotocininducedalzheimersdiseaseinwistarrats
AT kannansoundarapandian galantaminetetheredhydrogelasanoveltherapeutictargetforstreptozotocininducedalzheimersdiseaseinwistarrats